Overall survival (OS) of acute erythroid leukemia (AEL) patients by cytogenetic risk grouping. (A) The median OS of patients in the UKMRC AML intermediate and unfavorable groups was 30 and 6 months, respectively (P < .001). (B) The median OS of patients in the IPSS MDS good-, intermediate-, and poor-risk groups was 30, 23, and 6 months, respectively. The poor IPSS MDS risk group had a significantly inferior OS compared with the intermediate and good groups (both P < .001). There was no significant difference in OS between patients in the IPSS MDS good- and intermediate-risk groups (P = .68).